Floatz logo

Ap-Pa02

Lung Infection

Armata Pharmaceuticals, Inc.Phase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Lung Infection cohort.

Asset / SponsorPhaseRating
Linezolid
University Ghent
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Denver Health and Hospital Authority
Phase 4BB
Amikacin
Asian Institute of Gastroenterology, India
Phase 4BB
Penicillin
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3BB
NORMAL HUMAN SERUM ALBUMIN
EASL - CLIF Consortium
Phase 4BB

View all 26 →

Same molecule, other indications

Ap-Pa02 is also rated in:

Pseudomonas aeruginosa infectious diseaseDormant
BB
Indicative ·
69 / 100
View asset →
bronchiectasisDormant
B
Indicative ·
57 / 100
View asset →
Pseudomonas infectionDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →